04:28 PM EDT, 07/10/2025 (MT Newswires) -- Cogent Biosciences ( COGT ) said late Thursday it closed its upsized underwritten public offering of 25.6 million shares of common stock at $9 per share, for gross proceeds of about $230 million before deducting expenses.

The offering included the full exercise of the underwriters' option to purchase 3.3 million additional shares.

Cogent plans to use the net proceeds to support the development of regulatory and commercial activities relating to bezuclastinib and other products, as well as for general business operations.